Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cognition Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Cognition Therapeutics, Inc.’s stock price such as:

• Cognition Therapeutics, Inc.’s current stock price and volume
• Why Cognition Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CGTX from analysts
• CGTX’s stock price momentum as measured by its relative strength

About Cognition Therapeutics, Inc. (CGTX)

Before we jump into Cognition Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Want to learn more about Cognition Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cognition Therapeutics, Inc..

Cognition Therapeutics, Inc.’s Stock Price as of Market Close

As of December 23, 2025, 4:00 PM, CST, Cognition Therapeutics, Inc.’s stock price was $1.400.

Cognition Therapeutics, Inc. is down 11.95% from its previous closing price of $1.590.

During the last market session, Cognition Therapeutics, Inc.’s stock traded between $1.370 and $1.610. Currently, there are approximately 77.95 million shares outstanding for Cognition Therapeutics, Inc..

Cognition Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cognition Therapeutics, Inc. Stock Price History

Cognition Therapeutics, Inc.’s (CGTX) price is currently down 19.54% so far this month.

During the month of December, Cognition Therapeutics, Inc.’s stock price has reached a high of $1.810 and a low of $1.370.

Over the last year, Cognition Therapeutics, Inc. has hit prices as high as $3.830 and as low as $0.222. Year to date, Cognition Therapeutics, Inc.’s stock is up 99.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cognition Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of December 22, 2025,, no analysts have changed their rating of Cognition Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Cognition Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cognition Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cognition Therapeutics, Inc. (CGTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Cognition Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 22, 2025, Cognition Therapeutics, Inc. has a weighted four-quarter relative price strength of 55.23%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Cognition Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cognition Therapeutics, Inc. Stock Price: Bottom Line

As of December 23, 2025, Cognition Therapeutics, Inc.’s stock price is $1.400, which is down 11.95% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cognition Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.